Front Row Advisors LLC Arbutus Biopharma Corp Transaction History
Front Row Advisors LLC
- $282 Million
- Q2 2024
A detailed history of Front Row Advisors LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Front Row Advisors LLC holds 10,500 shares of ABUS stock, worth $41,370. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,500
Previous 10,500
-0.0%
Holding current value
$41,370
Previous $27,000
18.52%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ABUS
# of Institutions
138Shares Held
95.4MCall Options Held
3.44MPut Options Held
377K-
Morgan Stanley New York, NY21MShares$82.6 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$50.7 Million30.08% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$45.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.57MShares$33.8 Million10.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.02MShares$27.7 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $591M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...